ARKG — ARK Genomic Revolution ETF (ETF)

Price: $51.3 · 1 day: +4.08% · 5 days: -5.00% · 1 month: +10.78% · YTD: +77.08%
As of 2026-10-09 20:00 UTC.

52-week range: $24.6 – $58.83 (currently at 78% of the range).

The read

ARKG is in an uptrend, momentum soft. $56.77 is the level overhead; $50 the first support below.

3 of 6 technical checks lean bullish.

• Price vs 50-day: above
• Price vs 200-day: above
• 50d vs 200d avg: above
• MACD: bearish
• RSI momentum: 49
• 5-day tape: -5.0%

Key levels

Indicators

Latest ARKG news

• Here are Thursday's biggest analyst calls: Nvidia, Apple, SpaceX, Palantir, Microsoft, Generac, Netflix & more — Wall Street analysts issued numerous bullish calls on Thursday across multiple sectors, with key upgrades including Goldman Sachs upgrading Palantir to buy with a $230 price target, Morgan Stanley reiterating Microsoft a (CNBC, 2026-10-08)
• From Platform Knowledge to Commercial Readiness: Accelerating and De-risking your AAV Therapy's Path to Patients, Upcoming Webinar Hosted by Xtalks — Xtalks is hosting a free webinar on October 13, 2026, at 11am EDT, focused on accelerating and de-risking adeno-associated virus (AAV) gene therapy commercialization. The session will cover process characterization, cont (PR Newswire, 2026-09-30)
• Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsight — The retinitis pigmentosa market is projected to experience steady growth through 2036, driven by advances in gene therapy, increased genetic testing adoption, and an expanding clinical pipeline of disease-modifying thera (PR Newswire, 2026-09-29)
• BiomEdit's First-of-its-Kind Engineered Bacterial Biologic for Poultry Receives Conditional Licensure from USDA — BiomEdit received conditional licensure from the USDA for CPerf LLV, a first-of-its-kind engineered bacterial biologic for poultry, targeting necrotic enteritis. The product demonstrated a 48.7% reduction in NE-associate (PR Newswire, 2026-09-29)
• Minaris Evolves Business Model with Addition of Dedicated Viral Vectors Business Unit — Minaris, a global cell and gene therapy (CGT) CDMO and contract testing organization, announced the addition of a dedicated Viral Vectors business unit, effective October 1, 2026. The company will now operate through thr (PR Newswire, 2026-09-29)
• Liquid Handling System Market worth $7.79 billion by 2031 - Exclusive Report by MarketsandMarkets™ — MarketsandMarkets projects the global liquid handling system market will grow from USD 5.26 billion in 2026 to USD 7.79 billion by 2031, representing a compound annual growth rate (CAGR) of 8.2%. The automated systems se (PR Newswire, 2026-09-25)
• Why Wall Street Got Anthropic's Big DNA Discovery So Wrong — Anthropic's Claude AI identified a novel DNA repeat pattern resembling CRISPR, though its function remains unknown, and the discovery coincided with declines in gene-editing stocks: Prime Medicine fell 11.58%, Beam Thera (Forbes, 2026-09-25)
• Meta Seeks Success Where Others Failed With New AI Lineup — ```json { "summary": "Meta is launching a new lineup of AI-infused consumer electronics products as the company expands beyond social media and advertising. The expansion represents Meta's attempt to succeed in hardwar (Bloomberg Business, 2026-09-25)

Explore more

Interactive ARKG chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs